BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18690094)

  • 1. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
    Koizumi W; Okayasu I; Hyodo I; Sakamoto J; Kojima H;
    Anticancer Drugs; 2008 Sep; 19(8):819-24. PubMed ID: 18690094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
    Boskos CS; Liacos C; Korkolis D; Aygerinos K; Lamproglou I; Terpos E; Stoupa E; Baltatzis G; Beroukas K; Papasavvas P; Dimopoulos MA; Bamias A
    J Surg Oncol; 2010 Oct; 102(5):408-12. PubMed ID: 19877119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
    Saif MW; Black G; Roy S; Bell D; Russo S; Eloubeidi MA; Steg A; Johnson MR; Zelterman D; Diasio RB
    Cancer J; 2007; 13(4):247-56. PubMed ID: 17762760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine.
    Nishina T; Hyodo I; Miyaike J; Inaba T; Suzuki S; Shiratori Y
    Eur J Cancer; 2004 Jul; 40(10):1566-71. PubMed ID: 15196541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
    Saif MW; Eloubeidi MA; Russo S; Steg A; Thornton J; Fiveash J; Carpenter M; Blanquicett C; Diasio RB; Johnson MR
    J Clin Oncol; 2005 Dec; 23(34):8679-87. PubMed ID: 16314628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
    Saif MW; Hashmi S; Bell D; Diasio RB
    Expert Opin Drug Saf; 2009 Sep; 8(5):507-14. PubMed ID: 19663627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
    Garcia AA; Blessing JA; Lenz HJ; Darcy KM; Mannel RS; Miller DS; Husseinzadeh N;
    Gynecol Oncol; 2005 Mar; 96(3):810-7. PubMed ID: 15721430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
    Saito K; Khan K; Yu SZ; Ronson S; Rhee J; Li G; Van Echo D; Suntharalingam M; O'Malley BW; Li D
    Laryngoscope; 2009 Jan; 119(1):82-8. PubMed ID: 19117293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix.
    Hasegawa K; Okamoto H; Kawamura K; Kato R; Kobayashi Y; Sekiya T; Udagawa Y
    Eur J Obstet Gynecol Reprod Biol; 2012 Jul; 163(1):67-70. PubMed ID: 22480411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults.
    Patel A; Pluim T; Helms A; Bauer A; Tuttle RM; Francis GL
    Cancer Chemother Pharmacol; 2004 May; 53(5):409-14. PubMed ID: 15132128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results.
    Honda J; Sasa M; Moriya T; Bando Y; Hirose T; Takahashi M; Nagao T; Tangoku A
    J Med Invest; 2008 Feb; 55(1-2):54-60. PubMed ID: 18319546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.
    Nishimura G; Terada I; Kobayashi T; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Kayahara M; Shimizu K; Ohta T; Miwa K
    Oncol Rep; 2002; 9(3):479-82. PubMed ID: 11956613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential].
    Stepanova EV; Bokhian BIu; Petrovichev NN; Lichinitzer MR
    Vopr Onkol; 2005; 51(3):314-6. PubMed ID: 16279094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
    Vallböhmer D; Yang DY; Kuramochi H; Shimizu D; Danenberg KD; Lindebjerg J; Nielsen JN; Jakobsen A; Danenberg PV
    Int J Oncol; 2007 Aug; 31(2):413-8. PubMed ID: 17611699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in gastric and colorectal cancers.
    Hotta T; Taniguchi K; Kobayashi Y; Johata K; Sahara M; Naka T; Watanabe T; Ochiai M; Tanimura H; Tsubota YT
    Oncol Rep; 2004 May; 11(5):1045-51. PubMed ID: 15069545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
    Amatori F; Di Paolo A; Del Tacca M; Fontanini G; Vannozzi F; Boldrini L; Bocci G; Lastella M; Danesi R
    Pharmacogenet Genomics; 2006 Nov; 16(11):809-16. PubMed ID: 17047489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
    Tahara M; Ochiai A; Fujimoto J; Boku N; Yasui W; Ohtsu A; Tahara E; Yoshida S
    Oncol Rep; 2004 Jan; 11(1):9-15. PubMed ID: 14654896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in human breast carcinoma cells and tissues.
    Loo WT; Chow LW; Suzuki T; Ono K; Ishida T; Hirakawa H; Ohuchi N; Sasano H
    Anticancer Res; 2009 Jul; 29(7):2525-30. PubMed ID: 19596923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
    Wan Y; Hui H; Wang X; Wu J; Sun S
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.